Oral biologics beyond nature,
engineered by AI
Modern peptides drugs require several chemical building blocks beyond the natural amino acids.
Current techniques to develop these drug-like properties are limited to a fraction of the potential design space.
Could AI be used to discover medicines beyond nature?
DaX™
A novel AI model emerged from Caltech that enables ncAA peptide design
Pioneered by Caltech Professor David Van Valen, MD, PhD
Training a foundation model to learn the underlying physics and geometry of receptor-ligand interactions
e.g. D-amino acidGuided diffusion to design modern peptide drugs, not binders
Delivering Oral Biologics for patient benefit
e.g. cytokine inhibition
Our Pipeline
Aizen is developing a portfolio of oral peptide therapeutics to transform the lives of patients and families burdened by chronic immune disorders.
Reach out to us at partnering@aizentx.com to learn more.